AC Immune Expects Three-Year Cash Runway With Cash Balance Of CHF 104.8M At Q1 End, Plus $100M Upfront From Takeda And The Anticipated ACI-35.030-Related CHF 25M Milestone
Portfolio Pulse from Benzinga Newsdesk
AC Immune reported a cash balance of CHF 104.8M at the end of Q1 and expects a three-year cash runway. This is bolstered by a $100M upfront payment from Takeda and an anticipated CHF 25M milestone related to ACI-35.030.
May 13, 2024 | 10:14 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
AC Immune's financial position is strengthened by its Q1 cash balance and partnerships, indicating a stable outlook for the next three years.
The reported cash balance and the additional funds from Takeda provide a significant boost to AC Immune's financial stability and future prospects. This positive financial news is likely to instill confidence in investors, potentially leading to a short-term uptick in ACIU's stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100